Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)
Study Details
Study Description
Brief Summary
This study is a single center cohort study to access the anti-tumor efficacy, safety and tolerability of DZD9008 in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) sensitizing mutations and EGFR uncommon mutations who have progressed following standard TKI therapy, and in treatment naive patients with NSCLC harboring EGFR Exon20 insertion mutation.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Cohort 1: EGFR sensitizing mutations, T790M neg
|
Drug: DZD9008
Daily dosing of DZD9008
|
| Experimental: Cohort 2: EGFR sensitizing mutations
|
Drug: DZD9008
Daily dosing of DZD9008
|
| Experimental: Cohort 3: EGFR uncommon mutations
|
Drug: DZD9008
Daily dosing of DZD9008
|
| Experimental: Cohort 4: EGFR Exon20ins
|
Drug: DZD9008
Daily dosing of DZD9008
|
Outcome Measures
Primary Outcome Measures
- Progression-free survival (PFS) [through study completion, an average of 1 year]
To assess anti-tumor activity of DZD9008 according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator
Secondary Outcome Measures
- Duration of Response (DoR) [through study completion, an average of 1 year]
To assess anti-tumor activity of DZD9008 according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator
Other Outcome Measures
- Disease Control rate (DCR) [through study completion, an average of 1 year]
To assess anti-tumor activity of DZD9008 according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator
- Objective Response Rate (ORR) [through study completion, an average of 1 year]
To assess anti-tumor activity of DZD9008 according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator
- Overall survival (OS) [through study completion, an average of 1 year]
To assess anti-tumor activity of DZD9008 according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator
- Number of participants with adverse events (AEs) according to CTCAE 5.0 [From first dose until 28 days after the last dose]
To assess safety and tolerability of DZD9008 when given orally to patients with advanced NSCLC
- Number of participants with clinically significant laboratory assessment abnormalities [From first dose until 28 days after the last dose]
To assess safety and tolerability of DZD9008 when given orally to patients with advanced NSCLC
- Number of participants with clinically significant abnormal vital signs [From first dose until 28 days after the last dose]
To assess safety and tolerability of DZD9008 when given orally to patients with advanced NSCLC
- Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities [From first dose until 28 days after the last dose]
To assess safety and tolerability of DZD9008 when given orally to patients with advanced NSCLC
Eligibility Criteria
Criteria
Inclusion Criteria:
-
To provide a signed and dated, written informed consent.
-
Aged ≥ 18 years old
-
Histologically or cytologically confirmed locally advanced or metastatic NSCLC with documented EGFR mutations from a local laboratory
-
ECOG performance status 0-1.
-
Predicted life expectancy ≥ 12 weeks
-
Patient must have measurable disease according to RECIST 1.1.
-
Patient who has progressed or intolerant to standard therapy (except treatment naïve patient with EGFR Exon20ins in Cohort 4).
-
Patients with brain metastasis (BM) can be enrolled under the condition that BM is stable, neurologically asymptomatic and does not require corticosteroid treatment.
-
Adequate organ system function.
-
Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L
-
Platelets ≥ 100 x 10^9/L
-
Hemoglobin ≥ 9 g/dL
-
Total bilirubin ≤ 1.5 x ULN if no liver metastases or ≤ 3 x ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases
-
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN if no liver metastases or ≤ 5 x ULN with liver metastases
-
Creatinine ≤ 1.5 x ULN, concurrent with calculated or measured creatinine clearance ≥ 50 mL/min as calculated by the Cockcroft-Gault method or ≥ 50 mL/min in 24 hours
-
International normalized ratio (INR) ≤ 1.5 x ULN and activated partial thromboplastin time (APTT) ≤ 1.5 x ULN;
-
Serum amylase ≤ 1.5 x ULN and serum lipase ≤ 1.5 x ULN
Exclusion Criteria:
-
Known history of bleeding diathesis.
-
Prior malignancy within 2 years requires active treatment.
-
Any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of first administration.
-
History of stroke or intracranial haemorrhage within 6 months before the first administration.
-
Spinal cord compression or leptomeningeal metastasis.
-
As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, which would jeopardize compliance with the protocol, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).
-
Any of the following cardiac criteria:
-
Mean resting corrected QT interval (QTcF) > 470 msec obtained from 3 electrocardiograms (ECGs);
-
Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG, e.g., complete left bundle branch block, third degree heart block, and second-degree heart block, PR interval > 250 msec.
-
Any factors that increase the risk of QTcF prolongation, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medication known to prolong the QT interval.
-
Prior history of atrial fibrillation within 6 months of first administration of DZD9008, except prior drug treatment related and recovered.
-
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
-
Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of DZD9008.
-
History of hypersensitivity to active or inactive excipients of DZD9008 or drugs with a similar chemical structure or class to DZD9008.
-
Women who are pregnant or breast feeding.
-
Involvement in the planning and conduct of the study.
-
Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements."
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital | Beijing | Beijing | China | 100730 |
Sponsors and Collaborators
- Peking Union Medical College Hospital
- Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DZ2021E0006